|
4 documents found matching dt:photograph.
|
|
Prev
Next
|
|
|
|
Showing 1-4 of 4 documents
|
1.
Covered Drugs and Services
|
Document Date:
|
20010700
|
|
Corporate Author:
|
Wisconsin Medicaid and BadgerCare
|
|
Search Terms in Context:
|
pgNbr=1
orisn Medicaid
-vu~r only the
legend drug
products of
manufacturers who
have sgned an
annual rebate
agreement wth
the federal Heath
Care Financing
Adminitraton.
Covered Drugs and Services
Wisconsin Medicaid covers most legend drugs
and a limited number of over-the-counter
(OTC) drugs.
Legend Drugs
As defined under HFS 101.03(94), Wis.
Admin. Code, a legend drug is any drug that
requires a prescription under federal code 21
USC 353(b). Legend drugs are covered by
Wisconsin Medicaid when.
The drug is approved by the Food and
Drug Administration (FDA) and is not on
the Negative Formulary List.
The manufacturer has signed the federal
rebate agreement for the drug.
The manufacturer has reported the drug
information to First DataBank.
Some drugs covered by Wisconsin Medicaid
may require prior authorization (PA), and
others require an appropriate diagnosis code
for reimbursement. Refer to Appendices 2 and
3 ofthis section for lists of Wisconsin Medicaid
covered drugs, including PA and diagnosis
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oya00a10
|
|
| |
2.
NDA #s 20-235, 20-882: Neurontin (Gabapentin) MACMIS #10738
|
Document Date:
|
20020107
|
|
Author:
|
Stockbridge, Lisa L
|
|
Corporate Author:
|
Department of Health & Human Services
|
|
Search Terms in Context:
|
pgNbr=1
DEPARTMENT OF HEALTH & HUMAN SERVICES
3
aao
TRANSMITTED BY FACSIMILE
O. Lucy Castro
Director, Worldwide Regulatory Strategy Pfizer, Inc.
235 East 42"d Street
New York, New York 10017-5755
Re: NDA #s 20-235, 20-882 Neurontin® (gabapentin) MACMIS # 10738
Dear Ms. Castro:
Through routine monitoring and surveillance, the Division of Drug Marketing, Advertising, and Communications (DDMAC) has identified a model (#NE 102254) for Neurontin (gabapentin) that is in violation of the Federal Food, Drug, and Cosmetic Act and applicable regulations because it makes representations about Neurontin which are false or misleading.
On one side, the model has a presentation of the human brain with full presentation of the hippocampus, the cerebellum, lower medullary structures leading to the spine, and the cerebrum with a prominent mention of the product name below. On the opposite side of the model is a heading "Mechanism of Action," under which are illustrations of cellular activity resulting from the administ
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/pna00a10
|
|
| |
3.
Covered Drugs and Services
|
Document Date:
|
20010700
|
|
Search Terms in Context:
|
pgNbr=1
_-C vered Drugs and Services
l
ii/
OdSi 1 Medicaid
cover only the
TA '
legend drug
productsof
manufacturers who
have signed an
annual rebate
agreement wth
the federal Heath
Care Financing
Adrri nitration.
Wisconsin Medicaid covers most legend drugs
and a limited number of over-the-counter
(OTC) drugs.
Legend Drugs
As defined under HFS 101.03(94), Wis.
Admin. Code, a legend drug is any drug that
requires a prescription under federal code 21
USC 353(b). Legend drugs are covered by
Wisconsin Medicaid when:
0
The drug is approved by the Food and
Drug Administration (FDA) and is not on
the Negative Formulary List.
The manufacturer has signed the federal
rebate agreement for the drug.
The manufacturer has reported the drug
information to First DataBank.
Some drugs covered by Wisconsin Medicaid
may require prior authorization (PA), and
others require an appropriate diagnosis code
for reimbursement. Refer to Appendices 2 and
3 ofthis section for lists of Wisconsin Medicaid
covered drugs, including
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/pta00a10
|
|
| |
4.
Website of Flavahan former Lab
|
Document Date:
|
20070213
|
|
Search Terms in Context:
|
Dr. Flavahan - Davis Heart Lung Research institute
Page 1 of 2
DoRöiw M. Davis
Heárt&Lung
;i-!¿AS^ie%^H-
::-ÏÏ;!:':^^!i!&S&.!^Av
RESEARCH Thematic Programs Research Labs Dr. Aievriadou Dr. Aitschuld Dr. Anderson Dr. Binkley Dr. Birmingham Dr. Garitón Dr. Cooke Dr, Crouser Dr. Doseff Dr. Flavahan Dr. Kuppusamy Dr. Marsh Dr. Moldovan Dr. Rovin Dr. Sen Dr. Strauch Dr. Wewers CSE
sísABOtfi»!
iiKkßEiMSö
«EM.
DR. FLAVAHAN
¿«XfMEife
site search
Home > Research > Research Labs > Dr, Flavahan
Flavahan Lab
Nicholas A. Flavahan, PhD
Heart & Lung Research Institute
The Ohio State University
545 Davis HLRI
473 West 12th Avenue
Columbus, Ohio 43210-1252
Phone: {614)688-4741
E - m a i I : fiavahan-l@medctr.05u.edu
Current Research
Cold-Induced Vasospasm, Raynaud's Phenomenon and Scleroderma
We have recently identified the molecular mechanism underlying cold-induced constriction or vasospasm of skin blood vessels. Vasospasm is exaggerated constriction or closure of blood vessels, which leads to e
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx14s10
|
|
| |
|
Prev
Next
|
